Acoltremon Suppliers & Bulk Manufacturers
Available Forms: Eye Drops
Available Strengths: 0.003%
Reference Brands: Tryptyr (USA)
Category:
Opthalmology
Acoltremon is available in Eye Drops
and strengths such as 0.003%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Acoltremon is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Acoltremon can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Acoltremon, marketed in the United States under the brand name TRYPTYR®, is a novel ophthalmic therapy developed for the treatment of the signs and symptoms of dry eye disease. It is formulated as eye drops and acts as a selective agonist of the TRPM8 thermoreceptor, a sensory receptor involved in ocular surface cooling and tear secretion. By activating TRPM8 receptors, acoltremon stimulates natural tear production, helping to restore the aqueous layer of the tear film that is often deficient in patients with dry eye disease.
Insufficient tear production is a key contributor to dry eye symptoms such as irritation, burning, and visual discomfort. Acoltremon addresses this underlying mechanism by promoting physiologic tear secretion rather than suppressing inflammation. During phase III clinical trials, acoltremon demonstrated a significant increase in tear production and showed a favorable safety profile, with a low rate of treatment discontinuation.
The successful clinical development of acoltremon represents an important milestone in dry eye management, introducing a first-in-class mechanism of action. Its approval provides a new therapeutic option for patients seeking effective and well-tolerated treatment for dry eye disease.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing